The Microenvironment in Myeloproliferative Neoplasms

被引:16
作者
Ramanathan, Gajalakshmi [1 ]
Fleischman, Angela G. [1 ,2 ]
机构
[1] Univ Calif Irvine, Dept Med, Div Hematol Oncol, 839 Hlth Sci Rd,Sprague Hall B100, Irvine, CA 92617 USA
[2] Univ Calif Irvine, Irvine Chao Family Comprehens Canc Ctr, Dept Biol Chem, 839 Hlth Sci Rd,Sprague Hall 126, Irvine, CA 92617 USA
基金
美国国家卫生研究院;
关键词
Inflammation; Microenvironment; Cytokines; Myeloproliferative neoplasm; Prognosis; Myeloid cells; MESENCHYMAL STROMAL CELLS; TYROSINE KINASE JAK2; ESSENTIAL THROMBOCYTHEMIA; POLYCYTHEMIA-VERA; TNF-ALPHA; MUTATIONS; ACTIVATION; THROMBOSIS; DISORDERS; MYELOFIBROSIS;
D O I
10.1016/j.hoc.2020.11.003
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic inflammation is a hallmark of myeloproliferative neoplasms (MPNs), with elevated levels of proinflammatory cytokines being commonly found in all 3 subtypes. Systemic inflammation is responsible for the constitutional symptoms, thrombosis risk, premature atherosclerosis, and disease evolution in MPN. Although the neoplastic clone and their differentiated progeny drive the inflammatory process, they also induce ancillary cytokine secretion from nonmalignant cells. Here, the authors describe the inflammatory milieu in MPN based on soluble factors and cellular mediators. They also discuss the prognostic value of cytokine measurements in patients with MPN and potential therapeutic strategies that target the cellular players in inflammation. © 2020 Elsevier Inc.
引用
收藏
页码:205 / 216
页数:12
相关论文
共 50 条
  • [22] Thrombosis in patients with myeloproliferative neoplasms. Case report
    Melikyan, Anait L.
    Subortseva, Irina N.
    Gilyazitdinova, Elena A.
    Koloshejnova, Tamara, I
    Shashkina, Kristina S.
    Egorova, Elena K.
    Kovrigina, Alla M.
    Sudarikov, Andrei B.
    Gorgidze, Lana A.
    TERAPEVTICHESKII ARKHIV, 2021, 93 (07) : 800 - 804
  • [23] Outcomes and predictors of survival in blast phase myeloproliferative neoplasms
    Lancman, Guido
    Brunner, Andrew
    Hoffman, Ronald
    Mascarenhas, John
    Hobbs, Gabriela
    LEUKEMIA RESEARCH, 2018, 70 : 49 - 55
  • [24] Quality of Life in Myeloproliferative Neoplasms Symptoms and Management Implications
    Mesa, Ruben
    Palmer, Jeanne
    Eckert, Ryan
    Huberty, Jennifer
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2021, 35 (02) : 375 - 390
  • [25] The prevalence of CALR mutations in a cohort of patients with myeloproliferative neoplasms
    Grinsztejn, E.
    Percy, M. J.
    Mcclenaghan, D.
    Quintana, M.
    Cuthbert, R. J. G.
    Mcmullin, M. F.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2016, 38 (01) : 102 - 106
  • [26] Role of Inflammatory Factors during Disease Pathogenesis and Stem Cell Transplantation in Myeloproliferative Neoplasms
    Chatain, Nicolas
    Koschmieder, Steffen
    Jost, Edgar
    CANCERS, 2020, 12 (08) : 1 - 19
  • [27] Mutations, inflammation and phenotype of myeloproliferative neoplasms
    Hermouet, Sylvie
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [28] Splanchnic vein thrombosis in myeloproliferative neoplasms
    Sekhar, Mallika
    McVinnie, Kathryn
    Burroughs, Andrew K.
    BRITISH JOURNAL OF HAEMATOLOGY, 2013, 162 (06) : 730 - 747
  • [29] Myeloproliferative neoplasms in adolescents and young adults
    Amerikanou, Rodothea
    Lambert, Jonathan
    Alimam, Samah
    BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2022, 35 (02)
  • [30] Thrombosis and platelet dysfunction in myeloproliferative neoplasms
    Mornet, C.
    Galinat, H.
    Mingant, F.
    Ianotto, J. C.
    Lippert, E.
    REVUE DE MEDECINE INTERNE, 2020, 41 (05): : 319 - 324